ARCHIMED, the healthcare-focused private equity firm, has held the final close of its fourth smallcap buyout fund, MED IV, at its €1.5bn hard cap. The fund was more than three times oversubscribed, comfortably exceeding its original €1.2bn target set at launch in January 2026. MED IV more than doubles the size of its predecessor, the €650m MED III fund, while continuing the series’ smallcap healthcare buyout strategy with a push toward a more diversified, global portfolio.

"The momentum behind MED IV reflects investors' confidence in our approach," said Denis Ribon, chairman and managing partner at the firm. "Investors like our healthcare specialization, top-decile DPI track-record, our proven alpha-focused Playbook, the well-structured and scalable platform, and our transparent governance and stable ownership."